Exicure to acquire GPCR USA from GPCR Therapeutic.

Exicure, an early-stage biotechnology company developing nucleic acid therapies targeting ribonucleic acid, agreed to acquire GPCR USA, the technology transfer and collaborative research on GPCR Therapeutics’ ongoing drug development pipelines, from GPCR Therapeutic, a clinical-stage international biopharmaceutical company. Financial terms were not disclosed.